Leads To Development is very interested in participating in EU Framework Programme for Research and Innovation “Horizon 2020”.

Horizon 2020 is the biggest research and innovation programme in the EU aimed at securing Europe's global competitiveness. H2020 is running from 2014 to 2020 with a budget of nearly €80 billion.

We are currently a consortium member in one FP7 project (CDVAX, see below) and we would be keen to join new, high-quality Horizon 2020 projects either as a SME partner organisation or on a contract research basis, bringing our expertise in preclinical and non-clinical development as well as in regulatory affairs.

Our experience and skills in rapidly advancing early development programmes from research into clinical stage products and beyond would provide an important boost to any translational medicine project.

Should there be an opportunity to collaborate, or for more information please contact Jonathan Kearsey at


CDVAX is a European Union 7th framework funded programme. The aim of CDVAX is to advance a novel and highly innovative oral vaccine that will provide protection against Clostridium difficile infection. Genetically engineered harmless bacteria will be used to generate the vaccine and protect against this serious and life-threatening hospital acquired infection. This project will develop and evaluate the vaccine up to and including a first-in-man clinical trial.